Sign in
Taking people in NetherlandsPhase 1/2

Tests MB-dNPM-1-TCR.1 in adults with relapsed or refractory acute myeloid leukemia

Tests MB-dNPM-1-TCR.1 in adults whose acute myeloid leukemia returned or did not respond.

Key facts

Who runs it
Miltenyi Biomedicine GmbH
Where
Leiden, NetherlandsSee the site
Registry title
A study of the safety and efficacy of MB-dNPM-1-TCR.1 in patients with relapsed or refractory AML.
Status
Recruiting
Phase
Phase 1/2
People taking part
32 people, planned
Started
1 Aug 2024
Expected to end
31 Mar 2032
Type of study
Interventional
Record updated
30 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with acute myeloid leukemia (AML) that has come back or has not responded to treatment.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Acute myeloid leukemia that has relapsed or is refractory (did not respond to treatment).

Where in Netherlands

  • Academisch Ziekenhuis LeidenLeiden, NetherlandsTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Plain-language title
Tests MB-dNPM-1-TCR.1 in adults with relapsed or refractory acute myeloid leukemiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
30 March 2026